ライフサイエンスコーパス: L-thyroxine

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 processes could be inhibited by probucol and L-thyroxine.

2 f vasopressin and either triiodothyronine or L-thyroxine.

3 f vasopressin and either triiodothyronine or l-thyroxine.

4 ids alone and steroids plus triiodothyronine/l-thyroxine also significantly reduced prolonged graft d

5 notube recognition complexes for riboflavin, L-thyroxine and oestradiol.

6 ata on the adverse effects of broader use of L-thyroxine are sparse.

7 This approach was tested using L-thyroxine as a model analyte.

8 ive stable isotopic thyroid hormone (13)C(6)-L-thyroxine as the label of which the binding to rTTR is

9 ia by solid phase synthesis with immobilised L-thyroxine, glucosamine, fumonisin B2 or biotin as temp

10 ols (CTL) and hypothyroid rats replaced with L-thyroxine (HT+T).

11 L-thyroxine (L-T4) malabsorption is a potential concern

12 with IC(50) values of 18-30 microM included L-thyroxine (L-T4), D-thyroxine (D-T4), 3,3', 5,5'-tetra

13 trol retinol-binding protein, vitamin A, and L-thyroxine levels in plasma and have the potential to m

14 suggests mechanisms for the inadequacies of l-thyroxine monotherapy and highlights the possible role

15 Thereafter, l-thyroxine monotherapy at doses to normalize the serum

16 The last sentence of the section titled "L-Thyroxine Monotherapy Fails to Restore All Markers of

17 s has brought into question the inability of l-thyroxine monotherapy to universally normalize serum T

18 sion provided a physiologic means to justify l-thyroxine monotherapy, obviating concerns about incons

19 les, retinol-binding protein, vitamin A, and L-thyroxine, notably influenced transthyretin amyloidoge

20 ter, after euthyroidism had been attained by L-thyroxine replacement therapy.

21 clear thyroid hormone receptor TRbeta1 (TR), L-thyroxine (T(4)) causes activation and nuclear translo

22 L-Thyroxine (T(4)) nongenomically promotes association o

23 ensitive method for the analysis of six THs, l-thyroxine (T(4)), 3,3',5-triiodo-l-thyronine (T(3)), 3

24 Activated nongenomically by l-thyroxine (T(4)), mitogen-activated protein kinase (MA

25 HeLa and CV-1 cells treated only with L-thyroxine (T4) demonstrated increased tyrosine phospho

26 The displacement of l-thyroxine (T4) from binding sites on transthyretin (TT

27 rum 3,5,3'-triiodothyronine (T3) with normal l-thyroxine (T4) levels, is associated with malignancy.

28 t evidence suggests that the thyroid hormone L-thyroxine (T4) stimulates growth of cancer cells via a

29 hyperthyroidism was generated by addition of L-thyroxine (T4) to drinking water.

30 of the label by the natural thyroid hormone l-thyroxine (T4), as a model analyte, is demonstrated in

31 Rats received placebo, 3.3-mg l-thyroxine (T4), or 20-mg T4 pellets (60-day release fo

32 Sprague-Dawley rats were injected daily with L-thyroxine (T4, 0.2 mg/kg s.c.).

33 sting vessels was increased 3-fold by either l-thyroxine (T4; 10(-7) mol/L) or 3,5,3'-triiodo-l-thyro

34 a membrane receptor, binds thyroid hormones (L-thyroxine, T4; 3,5,3'-triiodo-L-thyronine, T3) and is

35 currently reads "... for steady delivery of L-thyroxine").This has been corrected in the online vers

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。